Sanara (SMTI) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Sanara MedTech, Inc. (SMTI)

Biological agents for the therapy of severe tissue damage have become firmly established in surgical practice, guaranteeing stable demand for Sanara MedTech Inc. (SMTI) products. Current price action based on the EV/EBITDA multiple is 23.71, while the company retains leading specialists through prestige and lucrative compensation packages. Growth prospects rely on the commercial launch of new matrices and the integration of digital services into medicine.

Sanara MedTech, Inc. - SMTI Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/13/2026)

Analytical breakdowns for Sanara MedTech Inc.

- market price and analyst price targets:
Price Chart Sanara MedTech|SMTI - Analyst Median Target
- market capitalization details:
Market Value Sanara MedTech Inc.|SMTI - Enterprise Value
- book value of equity indicators:
Book Value per Share Sanara MedTech|SMTI - Book Valuation of Business|Market Value to Book Value Ratio sanaramedtech.com|SMTI - Total Business Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Sanara MedTech Inc.|SMTI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Sanara MedTech|SMTI - Company Aggregate Debts|Debt to Book Capitalization Ratio Sanara MedTech Inc.|SMTI - Company Long-Term Indebtedness|Company Short-Term Debts Sanara MedTech|Quick Liquidity sanaramedtech.com
- financial results and valuation multiples details:
SMTI - Final Profit|Projected Future Earnings Sanara MedTech Inc.|SMTI - P/E Multiple|Projected Price to Earnings Sanara MedTech|SMTI - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sanara MedTech Inc.|SMTI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Sanara MedTech|SMTI - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth sanaramedtech.com|SMTI - Earnings per share growth this year|Expected earnings per share growth for next year Sanara MedTech Inc.
Fundamental company analysis:SMTI (Sanara)
Original product of sanaramedtech.com

The EV/EBITDA multiple compares the total enterprise value of Sanara MedTech Inc. (SMTI) with its operating profit before depreciation, taxes, and interest. This metric allows for an assessment of the business's real value by neutralizing the impact of debt load and tax regimes. Stable demand for medical innovations makes such calculations a reliable analytical tool for this defensive asset. The EV/EBITDA trajectory of Sanara MedTech Inc. (SMTI) helps identify fundamental undervaluation or the risk of stagnant earnings in a timely manner.

Competitor analysis for Sanara MedTech Inc.

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Apogee Corp (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|DBVT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Solesence Beauty|Enterprise Value to Operating Income Before Depreciation DERM (Journey Medical Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Forte Biosciences, Inc. (FBRX)|Total Company Value to Operating Income Before Depreciation Ratio empro.my|EV/EBITDA Multiple SLGL (Sol-Gel Technologies Ltd.)|EV/EBITDA Multiple AXIL Brands Inc AXIL|MDCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VRCA (Verrica Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|HOTH: EV/EBITDA Multiple|Biofrontera (BFRI) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VYNE Therapeutics, Inc.|SNOA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QNRX|EV/EBITDA Multiple Azitra Corporation (AZTR)|Dermata Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ELAB|RVNC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization